Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

• Published in: Bezopasnostʹ i risk farmakoterapii (Online) Vol. 11; no. 2; pp. 215 - 230
• Main Authors: Fedyanin, M. Yu, Snegovoy, A. V., Breder, V. V., Linkova, Yu. N., Zinkina-Orikhan, A. V., Setkina, S. B., Fogt, S. N., Chistiakov, V. S., Kravtsova, N. A.
• Format: Journal Article
• Language: English; Russian
• Published: Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products 01.06.2023
• Subjects: biosimilar; clinical trials; immune-checkpoint inhibitors; immune-mediated adverse reactions; immune-related adverse events; immunotherapy; pd-1 inhibitor; pembrolizumab; pembroria

In recent years, there has been a significant increase in the number of patients with malignancies treated with immune checkpoint inhibitors (ICIs), including the anti-programmed cell death protein 1 (anti–PD-1) agent pembrolizumab. One of the important aspects of conducting clinical trials with ICI...